Clinical Trial Search

Primary: Number of Treatment-related Adverse Events — 6 Adverse events

Primary: Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) — 27.5; 91.6 percentage of participants

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events…

Primary: Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225 — 21; 12 Participants — p=0.1830

Primary: Subjects in Which the SLN(s) Are Identified — 27 Participants

Primary: Clinician Administered PTSD Scale (CAPS) — 43.2; 42.1; 25.8; 32.9 score on a scale — p=.002

Primary: Number of Participants With Adverse Experiences as Measured by Changes in Physical Examination of the Penis — 0; 0; 0 Participants

Primary: Overall Response Rate in "High Affinity" Group — 0.5 Proportion of participants

Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours

Primary: Progression Free Survival Using the RECIST 1.1 Criteria — 9.33; 11.30 months

Primary: Change From Baseline in Frequency of Dry Eye Symptoms (SANDE) — -8.0; -10.0; -15.0; -23.4 Frequency of symptoms per day

Primary: Treatment Completion Rate — 37 Participants

Primary: Percentage of Patients Who Are Able to Receive at Least One DLI Treatment — 36 Participants

Primary: Response Rate — 0; 0; 0 participants

Primary: Immune Response Rate — 0.29; 0.67 proportion of participants